These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31285178)

  • 21. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
    [No Abstract]   [Full Text] [Related]  

  • 22. Pembrolizumab for the treatment of non-small cell lung cancer.
    Muller M; Schouten RD; De Gooijer CJ; Baas P
    Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab shows promise in lung cancer.
    Cleghorn S
    Lancet Respir Med; 2015 Jun; 3(6):429. PubMed ID: 25935769
    [No Abstract]   [Full Text] [Related]  

  • 24. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report.
    Baby S; Khalil F; Tanvetyanon T
    Cancer Treat Res Commun; 2021; 28():100423. PubMed ID: 34166867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
    Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C
    J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769
    [No Abstract]   [Full Text] [Related]  

  • 27. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
    Lai CS; Boshoff C; Falzon M; Lee SM
    Thorax; 2006 Jan; 61(1):91. PubMed ID: 16396957
    [No Abstract]   [Full Text] [Related]  

  • 28. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
    Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.
    Zee YK; Chin TM; Wong AS
    J Clin Oncol; 2009 Oct; 27(30):e145-6. PubMed ID: 19667265
    [No Abstract]   [Full Text] [Related]  

  • 31. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
    Qin Q; Li B
    J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
    Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
    J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
    J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
    Qin A; Street L; Cease K; Viglianti BL; Warren EH; Zhao L; Ramnath N
    Clin Lung Cancer; 2017 Sep; 18(5):559-564. PubMed ID: 28366756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
    Ohashi K; Hotta K; Hirata T; Aoe K; Kozuki T; Ninomiya K; Kayatani H; Yanai H; Toyooka S; Hinotsu S; Takata M; Kiura K
    Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.